A5081896787- Acute Myeloid Leukemia Research
- Cancer Genomics and Diagnostics
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
- Chronic Myeloid Leukemia Treatments
- Influenza Virus Research Studies
- HER2/EGFR in Cancer Research
- Chronic Lymphocytic Leukemia Research
- Vascular Tumors and Angiosarcomas
- Endometrial and Cervical Cancer Treatments
- Advanced biosensing and bioanalysis techniques
- Uterine Myomas and Treatments
- Ovarian cancer diagnosis and treatment
- Medical Imaging and Pathology Studies
- Acute Lymphoblastic Leukemia research
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Pneumonia and Respiratory Infections
- Hematopoietic Stem Cell Transplantation
- Sarcoma Diagnosis and Treatment
- Respiratory viral infections research
- Cervical Cancer and HPV Research
- Lymphoma Diagnosis and Treatment
- Oral and Maxillofacial Pathology
- Abdominal Trauma and Injuries
- Hematological disorders and diagnostics
UMass Memorial Medical Center
2015-2024
University of Massachusetts Chan Medical School
2015-2024
Memorial Medical Center
2023
UPMC Presbyterian
2018
Memorial Hospital
2015
University of Chicago
2015
University of Pisa
2015
Azienda Ospedaliera Universitaria Pisana
2015
University of Iowa Hospitals and Clinics
2015
University of Bern
2015
Summary Recursive partitioning of healthy consortia led to the development Clonal Hematopoiesis Risk Score (CHRS) for clonal haematopoiesis (CH); however, in practical setting, most cases CH are diagnosed after patients present with cytopenias or related symptoms. To address this real‐world population, we characterize clinical trajectories 94 and distinguish harbouring canonical DNMT3A/TET2/ASXL1 mutations alone (‘sole DTA’) versus all other groups (‘non‐sole DTA’). TET2 , rather than DNMT3A...
aberrations constitute the highest risk subset of myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML). The International Consensus Classification questions blast threshold between MDS AML. In this study, we assess distinction AML for 76 patients with
Influenza is an acute respiratory illness caused by influenza A or B viruses that occur in outbreaks, mainly during the winter season. Rapid laboratory diagnosis of can help guide clinical management suspected patients effectively. Clinical sensitivities and specificities rapid diagnostic tests have varied considerably literature. Most these studies are evaluated using previously frozen stored specimens had tested positive. This study compares performance SOFIA A+B test to nucleic acid...
Intraoperative frozen section (IFS) on endometrial cancer is an invaluable skill for pathologists-in-training to master. Within limited time constraints, pathologists are expected determine tumor type, grade, and depth of myometrial invasion. During their training, pathology residents gradually gain experience in handling the majority cases. However, significant errors can still be seen among senior level trainees. We aimed improve training effectiveness by evaluating our trainees'...
Allogeneic stem cell transplant (allo-SCT) is a mainstay of treatment for acute myeloid leukemia (AML). Its success depends largely on response donor T lymphocytes against cells, known as graft-vs-leukemia (GvL) effect. A key potential driver GvL immune to mutation-derived neoantigens. Previous studies in solid tumors have demonstrated enhanced immunogenicity frameshift (FS)-derived peptides vs. those from non-synonymous single nucleotide variants (SNVs). We therefore hypothesized that AML...
A 31-year-old man with a history of giant cell tumor bone (GCTB) in the distal radius presents to clinic 9 years after en bloc resection. He was found have new soft tissue mass consistent GCTB and pulmonary metastases. Ultimately, he underwent excision his recurrence partial lobectomy for lung metastases.This case highlights importance having high level suspicion local or metastasis, even wide resection negative margins.
Allogeneic stem cell transplant (Allo-SCT) is a powerful tool in the treatment of acute myeloid leukemia (AML) and offers only potential chance cure. Crucial to success Allo-SCT elimination leukemic blasts prior transplant. Evaluation residual disease historically has been via morphologic review, with complete remission defined as fewer than 5% [1]. Although thresholds lower are prognostically significant [2], morphologically it usually impossible distinguish normal regenerating bone marrow...
Diffuse large B-cell lymphoma (DLBCL) accounts for approximately 25% of non-Hodgkin cases [1]. Although often treatment-responsive, 30–40% DLBCL patients develop refractory or relapsed ...